Yissum - Research Development Company of the Hebrew University

Raziel Therapeutics Ltd.

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Investment Opportunities in Startups and Spinoffs · Israel

Summary of the technology

Raziel Therapeutics Ltd.
Project ID : 6-2013-2894

Description of the technology

About the company

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose tissue. Raziel’s prime-candidate, RZL-012, is a first-in-class, currently in clinical development to treat obesity and related disorders. Raziel launched its clinical trial in the US at Q4 2015, expecting final data that include safety and efficacy, by mid of 2016.

Our technology

We become fat because we do not burn enough calories, yet consume extra food. Enhanced thermogenesis (=heat production) can correct this imbalance. Thermogenesis in large animals is different than that of small rodents and Raziel carefully verified that its drug acts in small and large mammals as well. Raziel’s novel drug is able to convert energy-storing white-adipose-tissue (WAT) into energy-burning brown- like adipose tissue, as evident by histological, cellular and molecular studies. Moreover, the physiological outcome of this tissue-remodeling is an outstanding local thermogenesis as clearly demonstrated in human-size pigs. This thermogenesis lasts for several months following a single treatment, with the ensuing ~30-50% reduction in s.c. fat at the treated site. The molecular target of Raziel proprietary drug was also identified and is part of Raziel IP.

Contact details



Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

Shmuel Ben-Sasson
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Socio-economic development models, economic aspects
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Other (uncategorised)
  • Investment Opportunities
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.